<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024721</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ESOL-301</org_study_id>
    <nct_id>NCT05024721</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and clinical efficacy of HIP2101 in&#xD;
      patients with acute or chronic gastritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rate of erosion</measure>
    <time_frame>week 2</time_frame>
    <description>percentage of subjects whose erosion score is improved by more than 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate of erosion</measure>
    <time_frame>week 2</time_frame>
    <description>percentage of subjects whose erosion is completely cured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure rate of edema</measure>
    <time_frame>week 2</time_frame>
    <description>percentage of subjects whose edema is completely cured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of erythema</measure>
    <time_frame>week 2</time_frame>
    <description>percentage of subjects whose erythema score is improved by more than 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of hemorrage</measure>
    <time_frame>week 2</time_frame>
    <description>percentage of subjects whose hemorrage score is improved by more than 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of GI symptoms</measure>
    <time_frame>week 2</time_frame>
    <description>percentage of subjects whose GI symptoms score is improved by more than 50%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>HIP2101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking HIP2101+HPP2102 once daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLD2101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking RLD21012101+HPP2101 once daily for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP2101</intervention_name>
    <description>Test drug</description>
    <arm_group_label>HIP2101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD2101</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>RLD2101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPP2101</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>RLD2101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPP2102</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>HIP2101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19≤ age ≤ 75&#xD;
&#xD;
          -  Have been diagnosed as acute or chronic gastritis with at least 1 erosion by endoscopy&#xD;
             within 7 days before enrollment.&#xD;
&#xD;
          -  Patients understood the consents and purpose of this trial and signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who cannot perform endoscopy&#xD;
&#xD;
          -  Active gastric or duodenal ulcer&#xD;
&#xD;
          -  Reflux esophagitis, barrett's esophagus, gastric or esophageal varix&#xD;
&#xD;
          -  Zollinger-Ellison syndrome, pyloric obstruction, and esophageal stricture,&#xD;
             Inflammatory Bowel Diease, acute pancreatitis&#xD;
&#xD;
          -  History of gastrointestinal surgery&#xD;
&#xD;
          -  History of malignancy tumor, especially in the upper gastrointestinal tract&#xD;
&#xD;
          -  Severe liver disorder(at screening day, AST or ALT level exceeds 3 times more than&#xD;
             normal upper range)&#xD;
&#xD;
          -  Severe renal disorder(at screening day, MDRD eGFP ≤ 30 mL/min/1.73m2) or chronic renal&#xD;
             disease&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Patients who have taken drugs containing following list within 2 weeks before&#xD;
             endoscopy : H2-receptor antagonists, Proton pump inhibitors, P-CABs, gastrin&#xD;
             inhibitors, antacids, gastric mucosal protectants, anticholinergics&#xD;
&#xD;
          -  Patients who have taken anticoagulants within a week before endoscopy&#xD;
&#xD;
          -  Patients who have taken drugs containing following list after endoscopy : GI tract&#xD;
             regulators, salicylates, steroids, , NSAIDs, bisphosphonates, selective serotonin&#xD;
             reuptake inhibitors, iron supplements, oriental herbal medicines&#xD;
&#xD;
          -  History of allergic reaction to the medications used in this study&#xD;
&#xD;
          -  Use of other investigational drugs within 30 days prior to the study&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Positive to pregnancy test, nursing mother, intention on pregnancy&#xD;
&#xD;
          -  Considered by investigator as not appropriate to participate in the clinical study&#xD;
             with other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-A Jung, Ph.D</last_name>
    <phone>82-2-410-9038</phone>
    <phone_ext>9038</phone_ext>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-A Jung</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hunyong Jung, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hun Young Jung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

